Narcolepsy, idiopathic hypersomnia and other central disorders of hypersomnolence
HRMYHarmony Biosciences Holdings IncCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for BP1.15205 in Narcolepsy, idiopathic hypersomnia and other central disorders of hypersomnolence. The expected timing is based on the latest available company guidance and may change.
11/19/25– Initiated first-in-human study. Topline data in 2026. 01/12/26:- First subject dosed in Ph1 PK trial; Phase 1 PK data expected in mid-2026. 02/24/26:- Phase 1 orexin-2 agonist trial ongoing; PK data expected mid-2026. 05/07/26:- SAD/MAD Ph1 ongoing; SAD PK/safety data, U.S. IND, and Ph1b start all targeted for mid–2H 2026. 08/04/26:- BP-205 Ph1 SAD data positive; MAD data expected Q4 2026; Ph1b data Early 2027.
Verification
Confirm timing and program details against the company announcement or filing.